Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
about
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerCalcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic InteractionsDocetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy.C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative reviewA phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.Docetaxel (taxotere) in the treatment of prostate cancer.Vitamin D prevents hypoxia/reoxygenation-induced blood-brain barrier disruption via vitamin D receptor-mediated NF-kB signaling pathways.Management of androgen-independent prostate cancer.Managing metastatic prostate cancer.Therapeutic options in androgen-independent prostate cancer: building on docetaxel.Docetaxel-associated epiphora.Management of prostate cancer. Part 3: metastatic disease.Vitamin D and cancer: clinical aspects.New molecular targets in advanced prostate cancer.Novel agents and targets in managing patients with metastatic prostate cancer.Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancerVitamin D and human health: lessons from vitamin D receptor null mice.Vitamin d: pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: a systematic review.Update in systemic therapy of prostate cancer: improvement in quality and duration of life.Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.New therapeutic targets in the treatment of prostate cancer.Role of autophagy in acute myeloid leukemia therapy.Emerging drugs for prostate cancer.Docetaxel-based combination therapy for castration-resistant prostate cancer.The role of vitamin D in cancer prevention and treatment.Castration-resistant prostate cancer: targeted therapies.Current treatment strategies for castration-resistant prostate cancerThe role of vitamin D in cancer prevention and treatment.Nutrition and physical activity guidelines for cancer survivors.Current progress in using vitamin D and its analogs for cancer prevention and treatment.Vitamin D, vitamin D analogs (deltanoids) and prostate cancer.Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
P2860
Q24684241-4711EDA4-6620-4DF7-B7AA-F99F99F21190Q26766242-B0E3C6A4-24BF-4938-9A4F-600BC8C90267Q33416977-781095AC-B3DC-4D6B-9E6D-9C24996C87B0Q33503237-83CBCA1B-915A-41E2-BEA0-8DE22C74004FQ33642278-4679963B-CA62-4DA8-A58B-3EDD67E1D9EEQ33802601-5C638CFD-1A8A-42C8-AD9A-5B80FF7363D8Q33949736-2B33A33E-F638-43D7-8DA1-9C52958FB0B0Q34718153-84C459B3-DFEA-4006-9BA4-9D1E5F61DC4BQ34799393-E672388D-C4E1-4C1E-B1D9-4B7157F28B08Q35143943-721198A4-086B-4D63-B1D9-0162B36AF54FQ35160177-ED9D6901-4C8D-4711-AF1A-199507102F87Q35588458-51E53237-8445-4FDE-BC3C-3191683D3063Q35996488-AEB30FC8-72B5-44EC-BC41-3AADCD1BE622Q36322784-0451A457-E557-4BB7-8D3C-E470AD79D3D7Q36344219-C1DB7CE6-E16A-42BC-BA19-626E40F0C36FQ36484970-61D505AF-1719-4F3D-8130-24285263BE69Q36499259-B9035EDC-1092-44CF-9641-EFAD16FC0E38Q36509508-973BB82C-9577-4849-B7D9-67DA58B0A2CDQ36532080-CCBCA7CD-D227-4C08-AE5E-F86E93D8DC0EQ36555662-6913E989-D8A1-4482-A494-258CC2985FB9Q36695826-4CECA401-0DBE-4776-A47C-CEF0928CE07AQ36973933-3AECAC4D-ECDD-445F-8EDC-6ADBE8B8A101Q37061744-309F4FE3-9158-4357-9AD9-7072A89A8823Q37086017-D5E9688E-42A9-4951-BBDA-DCA156406883Q37255452-AA2B1731-C93C-40B2-9B26-0DC83A0F9962Q37290963-DD1A0FD1-0092-4B94-ACA6-4E313EDB68E1Q37354063-8D916BCC-78A9-4F69-B572-B69C3B47D828Q37570555-FAD73C60-F663-4AFE-942A-01AFCB2162B9Q37721016-5DDB321A-660D-4D85-8FCD-5405F0DB120BQ37761548-E036A1C1-CF65-4769-888B-72865FD66F99Q37856646-7D02FF03-717F-46B6-B9A4-5B51821BB80CQ37860950-F982EADC-0C98-4627-9C6A-912D6583717BQ38004753-CDECCB2D-0D2A-4F9E-B5FD-0073820D8E7FQ38005959-627F8ADA-7FBF-4CB8-ACD4-67EA93B32297Q38020247-9B6FB1C1-EBC2-4582-9309-FA3338FB2D88Q38177358-FB6238EE-1C05-4DAD-86E0-5B05164F51B0Q38338010-DD8EF439-F9DD-4A5F-BE2F-FD36120ED66EQ38727418-A6D27B82-4103-49C6-A861-23CD5BC5B788Q39327525-626DEEFB-B5EB-4615-BE3A-1E6F238B94EFQ39687652-A815C268-D3D7-4453-8038-B8AFDE83BDC9
P2860
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Weekly high-dose calcitriol an ...... n-independent prostate cancer.
@en
Weekly high-dose calcitriol an ...... n-independent prostate cancer.
@nl
type
label
Weekly high-dose calcitriol an ...... n-independent prostate cancer.
@en
Weekly high-dose calcitriol an ...... n-independent prostate cancer.
@nl
prefLabel
Weekly high-dose calcitriol an ...... n-independent prostate cancer.
@en
Weekly high-dose calcitriol an ...... n-independent prostate cancer.
@nl
P2093
P356
P1476
Weekly high-dose calcitriol an ...... n-independent prostate cancer.
@en
P2093
Bruce A Lowe
Kristine M Eilers
Mark Garzotto
Merrill J Egorin
Tomasz M Beer
W David Henner
P304
P356
10.1200/JCO.2003.05.117
P407
P577
2003-01-01T00:00:00Z